Citations (150)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Fumiaki Ueno, Michio Doi, Yumi Kawai, Naoto Ukawa, Jordan Cammarota & Keith A. Betts. (2020) Number needed to treat and cost per remitter for biologic treatments of Crohn’s disease in Japan. Journal of Medical Economics 23:1, pages 80-85.
Read now
Read now
Kasper Vadstrup, Sarah Alulis, Andras Borsi, Sandra Elkjaer Stallknecht, Agnete Nielsen, Tine Rikke Jørgensen, Christina Wennerström, Niels Qvist & Pia Munkholm. (2020) Societal costs attributable to Crohn’s disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002–2016. Scandinavian Journal of Gastroenterology 55:1, pages 41-46.
Read now
Read now
Namita Tundia, Paulo Gustavo Kotze, Jorge Rojas Serrano, Mirhelen Mendes de Abreu, Martha Skup, Dendy Macaulay, James Signorovitch, Leonardo Chaves, Jingdong Chao & Yanjun Bao. (2016) Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn’s disease in Argentina, Brazil, Colombia, and Mexico. Journal of Medical Economics 19:12, pages 1187-1199.
Read now
Read now
Adam Gater, Helen Kitchen, Louise Heron, Catherine Pollard, Jonas Håkan-Bloch, Lise Højbjerre, Brian Bekker Hansen & Martin Strandberg-Larsen. (2015) Development of a conceptual model evaluating the humanistic and economic burden of Crohn’s disease: implications for patient-reported outcomes measurement and economic evaluation. Expert Review of Pharmacoeconomics & Outcomes Research 15:4, pages 643-656.
Read now
Read now
Paweł Kawalec & Krzysztof Piotr Malinowski. (2015) Indirect health costs in ulcerative colitis and Crohn’s disease: a systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research 15:2, pages 253-266.
Read now
Read now
Guy David, Candace Gunnarsson & Jennifer H. Lofland. (2015) Variations in care: a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease. Journal of Medical Economics 18:2, pages 137-144.
Read now
Read now
Monia Marchetti & Nicola Lucio Liberato. (2014) Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Review of Pharmacoeconomics & Outcomes Research 14:6, pages 815-824.
Read now
Read now
Jill M Augustine, Jeannie K Lee & Edward P Armstrong. (2014) Health outcomes and cost–effectiveness of certolizumab pegol in the treatment of Crohn’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 14:5, pages 599-609.
Read now
Read now
George J. Wan, Chris M. Kozma, Terra L. Slaton, William H. Olson & Brian G. Feagan. (2014) Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy. Journal of Medical Economics 17:6, pages 384-393.
Read now
Read now
Chureen T Carter, Heidi C Waters & Daniel B Smith. (2012) Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease. Patient Preference and Adherence 6, pages 417-426.
Read now
Read now
Ian S Zagon & Patricia J McLaughlin. (2011) Targeting opioid signaling in Crohn’s disease: new therapeutic pathways. Expert Review of Gastroenterology & Hepatology 5:5, pages 555-558.
Read now
Read now
Justin Bakhshai, Raymond Bleu-Lainé, Miah Jung, Jeanne Lim, Christian Reyes, Linda Sun, Charmaine Rochester & Fadia T. Shaya. (2010) The cost effectiveness and budget impact of natalizumab for formulary inclusion. Journal of Medical Economics 13:1, pages 63-69.
Read now
Read now
Articles from other publishers (138)
Yung Lee, Lauren Andrew, Sarah Hill, Kevin R. An, Louisa Chatroux, Sama Anvari, Dennis Hong & Angela H. Kuhnen. (2023) Disparities in access to minimally invasive surgery for inflammatory bowel disease and outcomes by insurance status: analysis of the 2015 to 2019 National Inpatient Sample. Surgical Endoscopy 37:12, pages 9420-9426.
Crossref
Crossref
Alexandra Feathers, Gina S Lovasi, Zoya Grigoryan, Kade Beem, Samit K Datta, David M Faleck, Thomas Socci, Rachel Maggi & Arun Swaminath. (2023) Crohn’s Disease Mortality and Ambient Air Pollution in New York City. Inflammatory Bowel Diseases.
Crossref
Crossref
Sahar Nasr, Ilyess Nsiri & Manel Ben Fredj. (2023) Effectiveness of smoking cessation interventions for smokers with Crohn’s disease: a systematic review. Future Science OA 9:7.
Crossref
Crossref
Olivia Kahn-Boesel, Sandhya Cautha, Nneka N. Ufere, Ashwin N. Ananthakrishnan & Bharati Kochar. (2023) A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States. American Journal of Gastroenterology Publish Ahead of Print.
Crossref
Crossref
Ferdinando D’Amico, Olga Tasopoulou, Gionata Fiorino, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Pierpaolo Sileri, Antonino Spinelli, Laurent Peyrin-Biroulet & Silvio Danese. (2023) Early Biological Therapy in Operated Crohn’s Disease Patients Is Associated With a Lower Rate of Endoscopic Recurrence and Improved Long-term Outcomes: A Single-center Experience. Inflammatory Bowel Diseases 29:4, pages 539-547.
Crossref
Crossref
Majid Pakdin, Leila Zarei, Kamran Bagheri Lankarani & Sulmaz Ghahramani. (2023) The cost of illness analysis of inflammatory bowel disease. BMC Gastroenterology 23:1.
Crossref
Crossref
Jason K C Tong, Tory Mascuilli, Christopher Wirtalla, Cary B Aarons, Nicole M Saur, Najjia N Mahmoud, Giorgos C Karakousis & Rachel R Kelz. (2022) Evaluating Changes in Surgical Outcomes for Patients With Inflammatory Bowel Disease Following Medicaid Expansion. Inflammatory Bowel Diseases.
Crossref
Crossref
Mafalda Santiago, Cláudia Camila Dias, Catarina Alves, Paula Ministro, Raquel Gonçalves, Diana Carvalho, Francisco Portela, Luís Correia, Paula Lago & Fernando Magro. (2022) The Magnitude of Crohn’s Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review. Inflammatory Bowel Diseases 28:10, pages 1527-1536.
Crossref
Crossref
Lorenzo Palamenghi, Polina Figliuc, Salvatore Leone & Guendalina Graffigna. (2022) Food and Inflammatory Bowel Diseases: A scoping review on the impact of food on patients’ psychosocial quality of life. Health & Social Care in the Community 30:5, pages 1695-1712.
Crossref
Crossref
Ryan C Ungaro, Jenny Griffith, Viviana Garcia-Horton, Aolin Wang & Raymond K Cross. (2022) Adalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn’s Disease: A Retrospective Claims Database Analysis. Crohn's & Colitis 360 4:3.
Crossref
Crossref
Ali Alshahrani & Abuzer Ali. (2022) Pre-Clinical Safety and Efficacy Evaluation of a Herbal Nanoemulsion-Based Formulation for Treating Inflammatory Bowel Disease. Journal of AOAC INTERNATIONAL 105:4, pages 1153-1161.
Crossref
Crossref
Soran R. Bozorg, Jonas Söderling, Åsa H. Everhov, Benjamin Lebwohl, Peter H.R. Green, Martin Neovius, Jonas F. Ludvigsson & Karl Mårild. (2022) Work Loss in Patients With Celiac Disease: A Population-based Longitudinal Study. Clinical Gastroenterology and Hepatology 20:5, pages 1068-1076.e6.
Crossref
Crossref
Ksenia O Gorbenko, Alexa Rae Riggs, Brooke Koeppel, Sydney Phlegar, Marla C Dubinsky, Ryan Ungaro & Laurie Keefer. (2021) Photovoice as a tool to improve patient—Provider communication in inflammatory bowel disease clinic: A feasibility study. Journal of Evaluation in Clinical Practice 28:1, pages 159-168.
Crossref
Crossref
Sulmaz Ghahramani, Zahra Tamartash, Mohammad Sayari, Homayoun Vahedi, Fatemeh Karimian, Sadegh Heydari & Kamran Bagheri Lankarani. (2022) Risk Factors Affecting 90-day Readmission of Patients with Inflammatory Bowel Disease. Middle East Journal of Digestive Diseases 14:1, pages 34-43.
Crossref
Crossref
Juraj Piestansky, Dominika Olesova, Michaela Matuskova, Ivana Cizmarova, Petra Chalova, Jaroslav Galba, Petra Majerova, Peter Mikus & Andrej Kovac. 2022.
139
213
.
Lichao Qiao, Lei Fang, Junyi Zhu, Yu Xiang, Haixia Xu, Xueliang Sun, Hongjin Chen & Bolin Yang. (2021) Total Flavone of Abelmoschus manihot Ameliorates TNBS-Induced Colonic Fibrosis by Regulating Th17/Treg Balance and Reducing Extracellular Matrix. Frontiers in Pharmacology 12.
Crossref
Crossref
Marie-Therese Schnorbach & Wolfgang Kruis. (2020) Krankheitskosten chronisch entzündlicher Darmerkrankungen in Deutschland. Zeitschrift für Gastroenterologie 59:11, pages 1173-1188.
Crossref
Crossref
Monica Y. Choe, Brigit VanGraafeiland & Alyssa Parian. (2021) Improving Follow-ups With Gastroenterologists Utilizing an Appointment Scheduling Protocol in Inflammatory Bowel Disease. Gastroenterology Nursing 44:5, pages E91-E100.
Crossref
Crossref
Reinier Cornelis Anthonius van Linschoten, Elyke Visser, Christa Diana Niehot, C. Janneke van der Woude, Jan Antonius Hazelzet, Desirée van Noord & Rachel Louise West. (2021) Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Alimentary Pharmacology & Therapeutics 54:3, pages 234-248.
Crossref
Crossref
Ting Zhou, Yanan Sheng & Haijing Guan. (2021) Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China. Advances in Therapy 38:8, pages 4233-4245.
Crossref
Crossref
Lauren Kuenstner & John Todd Kuenstner. (2021) Mycobacterium avium ssp. paratuberculosis in the Food Supply: A Public Health Issue. Frontiers in Public Health 9.
Crossref
Crossref
Michael Kurin, Alyce Anderson, Claudia Ramos Rivers, Filippos Koutroumpakis, Patricia Centa, Juliette Bender‐Heine, Gina Kozak, Elisabeth Kramer, Stephen J. O'Keefe, David C. Whitcomb, David J. Levinthal, Ioannis E. Koutroubakis, Michael A. Dunn, Jana G. Hashash & David G. Binion. (2020) Clinical Characteristics of Inflammatory Bowel Disease Patients Requiring Long‐Term Parenteral Support in the Present Era of Highly Effective Biologic Therapy. Journal of Parenteral and Enteral Nutrition 45:5, pages 1100-1107.
Crossref
Crossref
Daniel J. Stein. (2020) All Systems Go: Reconsidering Healthcare Costs in Inflammatory Bowel Disease. Digestive Diseases and Sciences 66:3, pages 660-661.
Crossref
Crossref
Alok Kumar Mantri, Priti Meena, Amarender Singh Puri, Ajay Kumar, Sanjeev Sachdeva, Siddharth Srivastava, K. Arivarasan & Shivakumar Varakanahali. (2021) Comparison of Interferon-Gamma Release Assay and Tuberculin Skin Test for the Screening of Latent Tuberculosis in Inflammatory Bowel Disease Patients: Indian Scenario. Tuberculosis Research and Treatment 2021, pages 1-10.
Crossref
Crossref
Mattias Neyt, Annick Christiaens, Marina Aloi, Lissy de Ridder, Nicholas M Croft, Sibylle Koletzko, Arie Levine, Dan Turner, Richard K Russell, Frank M Ruemmele & Gigi Veereman. (2021) Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment. JMIR Formative Research 5:1, pages e13888.
Crossref
Crossref
Genyan Liu, Yuqiao Xu, Shiyang Pan, Weijuan Song, Jia Wang, Fei Jin, Zhenzhen Cai, Yi Zhang & Xiang Qian. 2021. Clinical Molecular Diagnostics. Clinical Molecular Diagnostics
511
552
.
Ipek Sapci, Benjamin Click & Scott R. Steele. 2021. Inflammatory Bowel Disease. Inflammatory Bowel Disease
317
329
.
Amy L. Lightner, Jean H. Ashburn, Mantaj S. Brar, Michele Carvello, Pramodh Chandrasinghe, Anthony de Buck van Overstraeten, Phillip R. Fleshner, Gaetano Gallo, Paulo Gustavo Kotze, Stefan D. Holubar, Lillian M. Reza, Antonino Spinelli, Scott A. Strong, Philip J. Tozer, Adam Truong, Janindra Warusavitarne, Takayuki Yamamoto & Karen Zaghiyan. (2020) Fistulizing Crohn's disease. Current Problems in Surgery 57:11, pages 100808.
Crossref
Crossref
Benjamin Click, Rocio Lopez, Susana Arrigain, Jesse Schold, Miguel Regueiro & Maged Rizk. (2020) Shifting Cost-drivers of Health Care Expenditures in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 26:8, pages 1268-1275.
Crossref
Crossref
Mariabeatrice Principi, Nunzia Labarile, Francesco Paolo Bianchi, Antonella Contaldo, Silvio Tafuri, Enzo Ierardi & Alfredo Di Leo. (2020) The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. International Journal of Environmental Research and Public Health 17:12, pages 4549.
Crossref
Crossref
Anusha Chaparala, Deepak Poudyal, Hossam Tashkandi, Erin E. Witalison, Alexander A. Chumanevich, Jenna L. Hofseth, Ivy Nguyen, Olivia Hardy, Douglas L. Pittman, Michael D. Wyatt, Anthony Windust, Elizabeth A. Murphy, Mitzi Nagarkatti, Prakash Nagarkatti & Lorne J. Hofseth. (2020) Panaxynol, a bioactive component of American ginseng, targets macrophages and suppresses colitis in mice. Oncotarget 11:22, pages 2026-2036.
Crossref
Crossref
Prasad Minakshi, Rajesh Kumar, Mayukh Ghosh, Basanti Brar, Manju Barnela & Preeti Lakhani. (2020) Application of Polymeric Nano-Materials in Management of Inflammatory Bowel Disease. Current Topics in Medicinal Chemistry 20:11, pages 982-1008.
Crossref
Crossref
Johan Burisch, Hillel Vardi, Doron Schwartz, Michael Friger, Gediminas Kiudelis, Juozas Kupčinskas, Mathurin Fumery, Corinne Gower-Rousseau, Laszlo Lakatos, Peter L Lakatos, Renata D'Incà, Alessandro Sartini, Daniela Valpiani, Martina Giannotta, Naila Arebi, Dana Duricova, Martin Bortlik, Stefania Chetcuti Zammit, Pierre Ellul, Natalia Pedersen, Jens Kjeldsen, Jóngerð Maria Miné Midjord, Kári Rubek Nielsen, Karina Winther Andersen, Vibeke Andersen, Konstantinos H Katsanos, Dimitrios K Christodoulou, Viktor Domislovic, Zeljko Krznaric, Shaji Sebastian, Pia Oksanen, Pekka Collin, Luisa Barros, Fernando Magro, Riina Salupere, Hendrika Adriana Linda Kievit, Adrian Goldis, Ioannis P Kaimakliotis, Jens F Dahlerup, Carl Eriksson, Jonas Halfvarson, Alberto Fernandez, Vicent Hernandez, Svetlana Turcan, Elena Belousova, Ebbe Langholz, Pia Munkholm, Selwyn Odes, Niksa Turk, Silvija Cukovic-Cavka, Anastasia Nicolaou, Milan Lukas, Olga Shonová, Birgitte Blichfeldt, Dorte Marker, Katrine Carlsen, Petra Weimers, Clays Aalykke, Karen Kudsk, Ida Vind, Niels Thorsgaard, Alexandros Skamnelos, Dimitrios Politis, Zsuzsanna Vegh, Peterne Demenyi, Szabina Nemethne Kramli, Giualia Dal Piaz, Alessia Santini, Giulia Girardin, Limas Kupcinskas, Laimas Jonaitis, Irena Valantiene, Romanas Zykus, Ruta Kucinskiene, Daniela Lazar, Inna Nikulina, Luisa de Castro, Juan-Ramon Pineda, Santos Pereira, Jesus Martinez-Cadilla, Luciano Sanroman, Montserrat Figueira, David Martinez Ares, Jose-Ignacio Rodriguez-Prada, Amalia Carmona, Carlos Gonzalez-Portela, Ulla-Britt Widen, Sally Myers, Katherine Ashton & Emma Whitehead. (2020) Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. The Lancet Gastroenterology & Hepatology 5:5, pages 454-464.
Crossref
Crossref
Thomas Stalder, Nathalie Kapel, Sophie Diaz, Frédéric Grenouillet, Stéphane Koch, Samuel Limat, Franck Daval, Lucine Vuitton & Virginie Nerich. (2020) A systematic review of economic evaluation in fecal microbiota transplantation. Infection Control & Hospital Epidemiology 41:4, pages 458-466.
Crossref
Crossref
Gary R. Lichtenstein, Ahva Shahabi, Seth A. Seabury, Darius N. Lakdawalla, Oliver Díaz Espinosa, Sarah Green, Michelle Brauer & Robert N. Baldassano. (2020) Lifetime Economic Burden of Crohn’s Disease and Ulcerative Colitis by Age at Diagnosis. Clinical Gastroenterology and Hepatology 18:4, pages 889-897.e10.
Crossref
Crossref
Alain Schoepfer, Stephan R. Vavricka, Beat Brüngger, Eva Blozik & Caroline Bähler. (2020) Systematic analysis of therapeutic patterns and healthcare use during 12 months before inflammatory bowel disease-related hospitalization in Switzerland. European Journal of Gastroenterology & Hepatology 32:3, pages 350-357.
Crossref
Crossref
Bobby Lo, Ida Vind, Marianne Kajbaek Vester-Andersen, Flemming Bendtsen & Johan Burisch. (2020) Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort. Journal of Crohn's and Colitis 14:1, pages 53-63.
Crossref
Crossref
Yazed AlRuthia, Othman Alharbi, Abdulrahman M. Aljebreen, Nahla A. Azzam, Majid A. Almadi, Ohud H. Bahari, Khalid A. Almalki, Abdulaziz T. Atham, Ahmed S. Alanazi, Maria Saeed, Baraa HajkhderMullaissa, Mohammad Alsenaidy & Bander Balkhi. (2019) Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Effectiveness and Resource Allocation 17:1.
Crossref
Crossref
Di Wu, Hatem Kittana, Jiang Shu, Stephen D Kachman, Juan Cui, Amanda E Ramer-Tait & Janos Zempleni. (2019) Dietary Depletion of Milk Exosomes and Their MicroRNA Cargos Elicits a Depletion of miR-200a-3p and Elevated Intestinal Inflammation and Chemokine (C-X-C Motif) Ligand 9 Expression in Mdr1a Mice. Current Developments in Nutrition 3:12, pages nzz122.
Crossref
Crossref
Benjamin Click & Miguel Regueiro. (2019) The Inflammatory Bowel Disease Medical Home: From Patients to Populations. Inflammatory Bowel Diseases 25:12, pages 1881-1885.
Crossref
Crossref
Antanina Voit, Raymond K. Cross, Emily Bellavance & Andrea C. Bafford. (2019) Financial Toxicity in Crohn’s Disease. Journal of Clinical Gastroenterology 53:10, pages e438-e443.
Crossref
Crossref
E Joline de Groof, Toer W Stevens, Emma J Eshuis, Tjibbe J Gardenbroek, Judith E Bosmans, JM van Dongen, Bregje Mol, Christianne J Buskens, Pieter C F Stokkers, Ailsa Hart, Geert R D’Haens, Willem A Bemelman & Cyriel Y Ponsioen. (2019) Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial. Gut 68:10, pages 1774-1780.
Crossref
Crossref
Savini Lanka Britto, Mahesh Krishna & Richard Kellermayer. (2019) Weight loss is a sufficient and economical single outcome measure of murine dextran sulfate sodium colitis. FASEB BioAdvances 1:8, pages 493-497.
Crossref
Crossref
Ziad Bakouny, Fares Yared, Elie El Rassy, Rita Jabbour, Rachel Hallit, Nathalie Khoury, Khalil Honein & Joseph Bou Jaoude. (2019) Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn’s Disease. Journal of Clinical Gastroenterology 53:6, pages 409-417.
Crossref
Crossref
Åsa H Everhov, Hamed Khalili, Johan Askling, Pär Myrelid, Jonas F Ludvigsson, Jonas Halfvarson, Caroline Nordenvall, Martin Neovius, Jonas Söderling & Ola Olén. (2019) Work Loss Before and After Diagnosis of Crohn’s Disease. Inflammatory Bowel Diseases 25:7, pages 1237-1247.
Crossref
Crossref
Raheleh Sadat Hosseini, Fariborz Mansour-Ghanaei, Afshin Shafaghi, Amineh Hojati, Farahnaz Joukar, Zahra Atrkar Roushan, Fakhri Alsadat Hosseini & Sara Mavaddati. (2021) Exacerbation causes among inflammatory bowel disease patients in Guilan Province north of Iran. Journal of Coloproctology 39:02, pages 138-144.
Crossref
Crossref
Nadia Pillai, Mark Dusheiko, Michel H Maillard, Gerhard Rogler, Beat Brüngger, Caroline Bähler, Valérie E H Pittet, Claudia Anderegg, Peter Bauerfeind, Christoph Beglinger, Stefan Begré, Dominique Belli, José M Bengoa, Luc Biedermann, Beat Bigler, Janek Binek, Mirjam Blattmann, Stephan Boehm, Jan Borovicka, Christian P Braegger, Nora Brunner, Patrick Bühr, Bernard Burnand, Emanuel Burri, Sophie Buyse, Matthias Cremer, Dominique H Criblez, Philippe de Saussure, Lukas Degen, Joakim Delarive, Christopher Doerig, Barbara Dora, Gian Dorta, Mara Egger, Tobias Ehmann, Ali El-Wafa, Matthias Engelmann, Jessica Ezri, Christian Felley, Markus Fliegner, Nicolas Fournier, Montserrat Fraga, Pascal Frei, Remus Frei, Michael Fried, Florian Froehlich, Christian Funk, Raoul Ivano Furlano, Suzanne Gallot-Lavallée, Martin Geyer, Marc Girardin, Delphine Golay, Tanja Grandinetti, Beat Gysi, Horst Haack, Johannes Haarer, Beat Helbling, Peter Hengstler, Denise Herzog, Cyrill Hess, Klaas Heyland, Thomas Hinterleitner, Philippe Hiroz, Claudia Hirschi, Petr Hruz, Rika Iwata, Res Jost, Pascal Juillerat, Céline Keller, Christina Knellwolf, Christoph Knoblauch, Henrik Köhler, Rebekka Koller, Claudia Krieger-Grübel, Gerd Kullak- Ublick, Patrizia Künzler, Markus Landolt, Rupprecht Lange, Frank Serge Lehmann, Andrew Macpherson, Philippe Maerten, Michel H Maillard, Christine Manser, Michael Manz, Urs Marbet, George Marx, Christoph Matter, Rémy Meier, Martina Mendanova, Pierre Michetti, Benjamin Misselwitz, Bernhard Morell, Patrick Mosler, Christian Mottet, Christoph Müller, Pascal Müller, Beat Müllhaupt, Claudia Münger-Beyeler, Leilla Musso, Andreas Nagy, Michaela Neagu, Cristina Nichita, Jan Niess, Andreas Nydegger, Nicole Obialo, Carl Oneta, Cassandra Oropesa, Ueli Peter, Daniel Peternac, Laetitia Marie Petit, Franziska Piccoli- Gfeller, Julia Beatrice Pilz, Valérie Pittet, Nadia Raschle, Ronald Rentsch, Sophie Restellini, Jean-Pierre Richterich, Sylvia Rihs, Marc Alain Ritz, Jocelyn Roduit, Daniela Rogler, Gerhard Rogler, Jean-Benoît Rossel, Vanessa Rueger, Gaby Saner, Bernhard Sauter, Mikael Sawatzki, Michela Schäppi, Michael Scharl, Sylvie Scharl, Martin Schelling, Susanne Schibli, Hugo Schlauri, Sybille Schmid Uebelhart, Jean-François Schnegg, Alain Schoepfer, Frank Seibold, Mariam Seirafi, Gian-Marco Semadeni, David Semela, Arne Senning, Marc Sidler, Christiane Sokollik, Johannes Spalinger, Holger Spangenberger, Philippe Stadler, Michael Steuerwald, Alex Straumann, Bigna Straumann- Funk, Michael Sulz, Alexandra Suter, Joël Thorens, Sarah Tiedemann, Radu Tutuian, Stephan Vavricka, Francesco Viani, Jürg Vögtlin, Roland Von Känel, Alain Vonlaufen, Dominique Vouillamoz, Rachel Vulliamy, Jürg Wermuth, Helene Werner, Paul Wiesel, Reiner Wiest, Tina Wylie, Jonas Zeitz & Dorothee Zimmermann. (2019) The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years. Journal of Crohn's and Colitis 13:6, pages 744-754.
Crossref
Crossref
James A King, Fox E Underwood, Nicola Panaccione, Josh Quan, Joseph W Windsor, Paulo G Kotze, Siew C Ng, Subrata Ghosh, Peter L Lakatos, Tine Jess, Remo Panaccione, Cynthia H Seow, Shomron Ben-Horin, Johan Burisch, Jean-Frédéric Colombel, Edward V LoftusJrJr, Richard Gearry, Jonas Halfvarson & Gilaad G Kaplan. (2019) Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. The Lancet Gastroenterology & Hepatology 4:4, pages 287-295.
Crossref
Crossref
Daniel C. Baumgart, Laurent Misery, Sue Naeyaert & Peter C. Taylor. (2019) Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Frontiers in Pharmacology 10.
Crossref
Crossref
L. Schulte, M. Hohwieler, M. Müller & J. Klaus. (2019) Intestinal Organoids as a Novel Complementary Model to Dissect Inflammatory Bowel Disease. Stem Cells International 2019, pages 1-15.
Crossref
Crossref
He Huang, Su Xu, Fubin Huang, Xia Wang, Yong Chen & Zhaoshan Xu. (2018) A Meta-Analysis of Efficacy and Safety of Infliximab for Prevention of Postoperative Recurrence in Patients with Crohn’s Disease. BioMed Research International 2018, pages 1-10.
Crossref
Crossref
Amanda Hansson-Hedblom, Chrissy Almond, Fredrik Borgström, Indeg Sly, Dana Enkusson, Anders Troelsgaard Buchholt & Linda Karlsson. (2018) Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Åsa H Everhov, Hamed Khalili, Johan Askling, Pär Myrelid, Jonas F Ludvigsson, Jonas Halfvarson, Caroline Nordenvall, Jonas Söderling, Ola Olén & Martin Neovius. (2018) Sick Leave and Disability Pension in Prevalent Patients With Crohn’s Disease. Journal of Crohn's and Colitis 12:12, pages 1418-1428.
Crossref
Crossref
Alain Schoepfer, Stephan R. Vavricka, Beat Brüngger, Oliver Reich, Eva Blozik & Caroline Bähler. (2018) Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland. European Journal of Gastroenterology & Hepatology 30:8, pages 868-875.
Crossref
Crossref
Benjamin Click, Alyce M. Anderson, Claudia Ramos Rivers, Ioannis E. Koutroubakis, Jana G. Hashash, Michael A. Dunn, Marc Schwartz, Jason Swoger, Arthur Barrie, Eva Szigethy, Miguel Regueiro, Robert E. Schoen & David G. Binion. (2018) Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients. Journal of Clinical Gastroenterology 52:4, pages 319-325.
Crossref
Crossref
Renata de S. B. Fróes, Ana Teresa Pugas Carvalho, Antonio Jose de V. Carneiro, Adriana Maria Hilu de Barros Moreira, Jessica P. L. Moreira, Ronir R. Luiz & Heitor S. de Souza. (2017) The socio-economic impact of work disability due to inflammatory bowel disease in Brazil. The European Journal of Health Economics 19:3, pages 463-470.
Crossref
Crossref
Mirjana Stanic Benic, Vanja Giljaca & Vera Vlahovic-Palcevski. (2018) The impact of biological interventions on health-related quality of life in adults with Crohn's disease. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Christina Y. Ha & Asher Kornbluth. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
261
282
.
Caroline Bähler, Stephan R. Vavricka, Alain M. Schoepfer, Beat Brüngger & Oliver Reich. (2017) Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterology 17:1.
Crossref
Crossref
F. J. Fernández-Pérez, A. M. Moreno-García, J. Hinojosa-Guadix & F. M. Vera-Rivero. (2018) Impacto del tratamiento biológico en la hospitalización y en el coste de la enfermedad inflamatoria intestinal. PharmacoEconomics Spanish Research Articles 14:3-4, pages 93-99.
Crossref
Crossref
Caroline Bähler, Alain M. Schoepfer, Stephan R. Vavricka, Beat Brüngger & Oliver Reich. (2017) Chronic comorbidities associated with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 29:8, pages 916-925.
Crossref
Crossref
Eva M. Szigethy, John I. Allen, Marci Reiss, Wendy Cohen, Lilani P. Perera, Lili Brillstein, Raymond K. Cross, David A. Schwartz, Lawrence R. Kosinski, Joshua B. Colton, Elizabeth LaRusso, Ashish Atreja & Miguel D. Regueiro. (2017) White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 15:7, pages 986-997.
Crossref
Crossref
Mehdi Zobeiri, Homayoon Bashiri, Lotfollah Askari, Ali Asghar Keshavars, Ramin Tavvafzadeh, Kiomars Fatahi & Farid Najafi. (2017) Epidemiologic Characteristics of Patients with Inflammatory Bowel Disease in Kermanshah, Iran. Middle East Journal of Digestive Diseases 9:3, pages 164-169.
Crossref
Crossref
Gauraang Bhatnagar, Conrad Von Stempel, Steve Halligan & Stuart A Taylor. (2017) Utility of MR enterography and ultrasound for the investigation of small bowel Crohn's disease. Journal of Magnetic Resonance Imaging 45:6, pages 1573-1588.
Crossref
Crossref
Mark Bounthavong, Meng Li & Jonathan H. Watanabe. (2017) An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Research in Social and Administrative Pharmacy 13:3, pages 530-538.
Crossref
Crossref
Richard T. Griffey, Kathryn J. Fowler, Andrew Theilen & Alexandra Gutierrez. (2017) Considerations in Imaging Among Emergency Department Patients With Inflammatory Bowel Disease. Annals of Emergency Medicine 69:5, pages 587-599.
Crossref
Crossref
Benjamin Click, David G. Binion & Alyce M. Anderson. (2017) Predicting Costs of Care for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 15:3, pages 393-395.
Crossref
Crossref
Zachary T. Bitzer, Amy L. Wopperer, Benjamin J. Chrisfield, Ling Tao, Timothy K. Cooper, Jairam Vanamala, Ryan J. Elias, John E. Hayes & Joshua D. Lambert. (2017) Soy protein concentrate mitigates markers of colonic inflammation and loss of gut barrier function in vitro and in vivo. The Journal of Nutritional Biochemistry 40, pages 201-208.
Crossref
Crossref
E. J. Mao, G. S. Hazlewood, G. G. Kaplan, L. Peyrin-Biroulet & A. N. Ananthakrishnan. (2017) Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics 45:1, pages 3-13.
Crossref
Crossref
Bhavana B. Rao, Benjamin H. Click, Ioannis E. Koutroubakis, Claudia Ramos Rivers, Miguel Regueiro, Jason Swoger, Marc Schwartz, Jana Hashash, Arthur Barrie, Michael A. Dunn & David G. Binion. (2017) The Cost of Crohnʼs Disease. Inflammatory Bowel Diseases 23:1, pages 107-115.
Crossref
Crossref
M.L. Smythe. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
157
170
.
Gilles Boschetti, Stephane Nancey, Fady Daniel, Benjamin Pariente, Eric Lerebours, Bernard Duclos, Arnaud Bourreille, Guillaume Cadiot, Mathurin Fumery, Jacques Moreau, Philippe Marteau, Yoram Bouhnik, Edouard Louis & Bernard Flourié. (2016) Costs of Crohnʼs Disease According to Severity States in France. Inflammatory Bowel Diseases 22:12, pages 2924-2932.
Crossref
Crossref
Johanna Schoehl, Nicolae-Catalin Mechie, Harald Schwoerer, Onnen Moerer, Michael Quintel, Cordula Buck, Volker Ellenrieder, Albrecht Neesse & Ahmad Amanzada. (2016) Severe Acute Respiratory Distress Syndrome during Infliximab Therapy in a Patient with Crohn Disease. Case Reports in Gastroenterology 10:3, pages 574-580.
Crossref
Crossref
Christina Y. Ha & Asher Kornbluth. (2016) A Critical Review of Biosimilars in IBD. Inflammatory Bowel Diseases 22:10, pages 2513-2526.
Crossref
Crossref
Jennifer E. Thorne, Martha Skup, Namita Tundia, Dendy Macaulay, Cindy Revol, Jingdong Chao, Avani Joshi & Andrew D. Dick. (2016) Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis. Acta Ophthalmologica 94:5.
Crossref
Crossref
Jianfei Jiang, Benjamin Click, Alyce M Anderson, Ioannis E Koutroubakis, Claudia Ramos Rivers, Jana G Hashash, Michael A Dunn, Marc Schwartz, Jason Swoger, Arthur Barrie, Miguel Regueiro, Chung-Chou H Chang & David G Binion. (2016) Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. Clinical and Translational Gastroenterology 7:7, pages e181.
Crossref
Crossref
Benjamin Click, Claudia Ramos Rivers, Ioannis E. Koutroubakis, Dmitriy Babichenko, Alyce M. Anderson, Jana G. Hashash, Michael A. Dunn, Marc Schwartz, Jason Swoger, Leonard Baidoo, Arthur BarrieIIIIII, Miguel Regueiro & David G. Binion. (2016) Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases 22:6, pages 1442-1449.
Crossref
Crossref
Michael L. Ganz, Rebecca Sugarman, Rosa Wang, Brian Bekker Hansen & Jonas Håkan-Bloch. (2016) The Economic and Health-related Impact of Crohnʼs Disease in the United States. Inflammatory Bowel Diseases 22:5, pages 1032-1041.
Crossref
Crossref
Mercedes Vergara, Beatriz Sicilia, Luis Prieto, Francesc Casellas, Alexis Ramos, Fernando Gomollón & Xavier Calvet. (2016) Development and Validation of the Short Crohnʼs Disease Work Disability Questionnaire. Inflammatory Bowel Diseases 22:4, pages 955-962.
Crossref
Crossref
N. To, D. J. Gracie & A. C. Ford. (2016) Systematic review with meta‐analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. Alimentary Pharmacology & Therapeutics 43:5, pages 549-561.
Crossref
Crossref
Sasha Taleban, Martijn G. H. Van Oijen, Eric A. Vasiliauskas, Phillip R. Fleshner, Bo Shen, Andrew F. Ippoliti, Stephan R. Targan & Gil Y. Melmed. (2015) Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn’s Colitis. Digestive Diseases and Sciences 61:2, pages 550-559.
Crossref
Crossref
Ferdinand Knieling & Maximilian J Waldner. (2016) Light and sound - emerging imaging techniques for inflammatory bowel disease. World Journal of Gastroenterology 22:25, pages 5642.
Crossref
Crossref
D. Roggenbuck, D. Reinhold, D.C. Baumgart, P. Schierack, K. Conrad & M.W. Laass. 2016.
77
101
.
Jermain Kaminski. 2016. Boundaryless Hospital. Boundaryless Hospital
295
320
.
Gaetano C. Morreale, Maria Cappello & Antonio Craxì. 2016. Crohn’s Disease. Crohn’s Disease
15
30
.
Nathan P. Zwintscher, Puja M. Shah, Amit Argawal, Patrick M. Chesley, Eric K. Johnson, Christopher R. Newton, Justin A. Maykel & Scott R. Steele. (2015) The impact of perianal disease in young patients with inflammatory bowel disease. International Journal of Colorectal Disease 30:9, pages 1275-1279.
Crossref
Crossref
Jonathan R. Dillman, Ethan A. Smith, Ramon J. Sanchez, Michael A. DiPietro, Vera DeMatos-Maillard, Peter J. Strouse & Kassa Darge. (2015) Pediatric Small Bowel Crohn Disease: Correlation of US and MR Enterography. RadioGraphics 35:3, pages 835-848.
Crossref
Crossref
Aaron T. Sin, Jennifer L. Damman, David A. Ziring, Elizabeth E. Gleghorn, Manuel G. Garcia-Careaga, Roberto R. Gugig, Anna K. Hunter, Jennifer C. Burgis, Dorsey M. Bass & K. T. Park. (2015) Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, pages 1.
Crossref
Crossref
Mike van der Have, Lianne K. P. M. Brakenhoff, Sanne J. H. van Erp, Ad A. Kaptein, Max Leenders, Margreet Scharloo, Roeland A. Veenendaal, Désirée M. F. M. van der Heijde, Andrea E. van der Meulen-de Jong, Daan W. Hommes & Herma H. Fidder. (2015) Back/joint Pain, Illness Perceptions and Coping are Important Predictors of Quality of Life and Work Productivity in Patients with Inflammatory Bowel Disease: a 12-month Longitudinal Study. Journal of Crohn's and Colitis 9:3, pages 276-283.
Crossref
Crossref
David N. Floyd, Sue Langham, Hélène Chevrou Séverac & Barrett G. Levesque. (2014) The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review. Digestive Diseases and Sciences 60:2, pages 299-312.
Crossref
Crossref
Fanni Rencz. (2015) Biological therapy in inflammatory bowel diseases: Access in Central and Eastern Europe. World Journal of Gastroenterology 21:6, pages 1728.
Crossref
Crossref
Edward V. LoftusJrJr, Martha Skup, Ahmet Burak Ozbay, Eric Wu, Annie Guérin, Jingdong Chao & Parvez Mulani. (2014) The Impact of Moderate-to-severe Crohnʼs Disease on Employeesʼ Salary Growth. Inflammatory Bowel Diseases 20:10, pages 1734-1738.
Crossref
Crossref
Bente Mertz Nørgård, Jan Nielsen, Kirsten Fonager, Jens Kjeldsen, Bent Ascanius Jacobsen & Niels Qvist. (2014) The incidence of ulcerative colitis (1995–2011) and Crohn's disease (1995–2012) — Based on nationwide Danish registry data. Journal of Crohn's and Colitis 8:10, pages 1274-1280.
Crossref
Crossref
Shota Saito, Utako Shimizu, Zhang Nan, Junji Yokoyama, Mayumi Watanabe, Kenshi Terajima & Kohei Akazawa. (2014) A health economic analysis of combination therapy with infliximab plus elemental diet for moderately to severely active Crohn’s disease. Health 06:01, pages 107-114.
Crossref
Crossref
Dwarikanath Mahapatra, Peter J. Schuffler, Jeroen A. W. Tielbeek, Jesica C. Makanyanga, Jaap Stoker, Stuart A. Taylor, Franciscus M. Vos & Joachim M. Buhmann. (2013) Automatic Detection and Segmentation of Crohn's Disease Tissues From Abdominal MRI. IEEE Transactions on Medical Imaging 32:12, pages 2332-2347.
Crossref
Crossref
Monia Marchetti, Nicola L. Liberato, Antonio Di Sabatino & Gino R. Corazza. (2012) Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease. The European Journal of Health Economics 14:6, pages 853-861.
Crossref
Crossref
Derek H. Tang, Amanda R. Harrington, Jeannie K. Lee, Mark Lin & Edward P. Armstrong. (2013) A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease. Inflammatory Bowel Diseases 19:12, pages 2673-2694.
Crossref
Crossref
Yusuke Honzawa, Hiroshi Nakase, Minoru Matsuura, Hirokazu Higuchi, Takahiko Toyonaga, Kayoko Matsumura, Takuya Yoshino, Kazuichi Okazaki & Tsutomu Chiba. (2013) Prior use of immunomodulatory drugs improves the clinical outcome of endoscopic balloon dilation for intestinal stricture in patients with Crohn's disease. Digestive Endoscopy 25:5, pages 535-543.
Crossref
Crossref
João Costa, Fernando Magro, Daniel Caldeira, Joana Alarcão, Rita Sousa & António Vaz-Carneiro. (2013) Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 19:10, pages 2098-2110.
Crossref
Crossref
Wei Da, Jinshui Zhu, Long Wang & Yunmin Lu. (2013) Efficacy and Safety of Certolizumab Pegol for Crohn’s Disease: A Systematic Review and Meta-Analysis. Advances in Therapy 30:5, pages 541-553.
Crossref
Crossref
Candace Gunnarsson, Jie Chen, John A. Rizzo, Joseph A. Ladapo, Ahmad Naim & Jennifer H. Lofland. (2013) The Employee Absenteeism Costs of Inflammatory Bowel Disease. Journal of Occupational & Environmental Medicine 55:4, pages 393-401.
Crossref
Crossref
Edouard Louis, Robert Löfberg, Walter Reinisch, Anne Camez, Mei Yang, Paul F. Pollack, Naijun Chen, Jingdong Chao & Parvez M. Mulani. (2013) Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial. Journal of Crohn's and Colitis 7:1, pages 34-43.
Crossref
Crossref
Amosy E. M'koma. (2013) Inflammatory Bowel Disease: An Expanding Global Health Problem. Clinical Medicine Insights: Gastroenterology 6, pages CGast.S12731.
Crossref
Crossref
Julio Maria Fonseca Chebli. (2013) Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn’s disease patients. Medical Science Monitor 19, pages 716-722.
Crossref
Crossref
Victor A. Garcia-Angulo, Mauricio J. Farfan & Alfredo G. Torres. 2013. Escherichia coli. Escherichia coli
331
359
.
Neal Shahidi, Yi-Tzu Nancy Fu, Hong Qian & Brian Bressler. (2012) Performance of interferon-gamma release assays in patients with inflammatory bowel disease: A systematic review and meta-analysis. Inflammatory Bowel Diseases 18:11, pages 2034-2042.
Crossref
Crossref
H. Whiley, A. Keegan, S. Giglio & R. Bentham. (2012) Mycobacterium avium complex - the role of potable water in disease transmission. Journal of Applied Microbiology 113:2, pages 223-232.
Crossref
Crossref
J. Hinojosa, J.P. Gisbert, F. Gomollón & A. López San Román. (2012) Adherence of gastroenterologists to European Crohn's and Colitis Organisation Consensus on Crohn's disease: A real-life survey in Spain. Journal of Crohn's and Colitis 6:7, pages 763-770.
Crossref
Crossref
K. T. Park, Raymond Tsai, Felipe Perez, Lauren E. Cipriano, Dorsey Bass & Alan M. Garber. (2012) Cost-Effectiveness of Early Colectomy With Ileal Pouch-Anal Anastamosis Versus Standard Medical Therapy in Severe Ulcerative Colitis. Annals of Surgery 256:1, pages 117-124.
Crossref
Crossref
Derek H. Tang, Edward P. Armstrong & Jeannie K. Lee. (2012) Cost‐Utility Analysis of Biologic Treatments for Moderate‐to‐Severe Crohn's Disease. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32:6, pages 515-526.
Crossref
Crossref
S. Simoens, G. Dunselman, C. Dirksen, L. Hummelshoj, A. Bokor, I. Brandes, V. Brodszky, M. Canis, G. L. Colombo, T. DeLeire, T. Falcone, B. Graham, G. Halis, A. Horne, O. Kanj, J. J. Kjer, J. Kristensen, D. Lebovic, M. Mueller, P. Vigano, M. Wullschleger & T. D'Hooghe. (2012) The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Human Reproduction 27:5, pages 1292-1299.
Crossref
Crossref
Daniel Hommes, Jean-Frédéric Colombel, Paul Emery, Marco Greco & William J. Sandborn. (2012) Changing Crohn's disease management: Need for new goals and indices to prevent disability and improve quality of life. Journal of Crohn's and Colitis 6, pages S224-S234.
Crossref
Crossref
K. Rudi, P. Ricanek, T. Tannæs, S. Brackmann, G. Perminow & M.H. Vatn. 2012. Case Studies in Food Safety and Authenticity. Case Studies in Food Safety and Authenticity
130
137
.
John Janez Miklavcic, Kareena Leanne Schnabl, Vera Christine Mazurak, Alan Bryan Robert Thomson & Michael Thomas Clandinin. (2012) Dietary Ganglioside Reduces Proinflammatory Signaling in the Intestine. Journal of Nutrition and Metabolism 2012, pages 1-8.
Crossref
Crossref
Natalie A. Molodecky, Ing Shian Soon, Doreen M. Rabi, William A. Ghali, Mollie Ferris, Greg Chernoff, Eric I. Benchimol, Remo Panaccione, Subrata Ghosh, Herman W. Barkema & Gilaad G. Kaplan. (2012) Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. Gastroenterology 142:1, pages 46-54.e42.
Crossref
Crossref
E. Daudén, S. Castañeda, C. Suárez, J. García-Campayo, A.J. Blasco, M.D. Aguilar, C. Ferrándiz, L. Puig & J.L. Sánchez-Carazo. (2012) Integrated Approach to Comorbidity in Patients With Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 103, pages 1-64.
Crossref
Crossref
E. Daudén, S. Castañeda, C. Suárez, J. García-Campayo, A.J. Blasco, M.D. Aguilar, C. Ferrándiz, L. Puig & J.L. Sánchez-Carazo. (2012) Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermo-Sifiliográficas 103, pages 1-64.
Crossref
Crossref
K.T. Park, Felipe Perez, Raymond Tsai, Anita Honkanen, Dorsey Bass & Alan Garber. (2011) Cost-effectiveness Analysis of Adjunct VSL#3 Therapy Versus Standard Medical Therapy in Pediatric Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 53:5, pages 489-496.
Crossref
Crossref
Antonio Di Sabatino, Lucio Liberato, Monia Marchetti, Paolo Biancheri & Gino R. Corazza. (2011) Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Internal and Emergency Medicine 6:S1, pages 17-27.
Crossref
Crossref
Chureen T. Carter, Heidi C. Waters & Daniel B. Smith. (2011) Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs. Advances in Therapy 28:8, pages 671-683.
Crossref
Crossref
John Paul Leombruno, Geoffrey C. Nguyen, Paul Grootendorst, David Juurlink & Tom Einarson. (2011) Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiology and Drug Safety 20:8, pages 838-848.
Crossref
Crossref
K. T. Park & Dorsey Bass. (2011) Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States. Inflammatory Bowel Diseases 17:7, pages 1603-1609.
Crossref
Crossref
Anne Prenzler, Bernd Bokemeyer, J.-Matthias von der Schulenburg & Thomas Mittendorf. (2010) Health care costs and their predictors of inflammatory bowel diseases in Germany. The European Journal of Health Economics 12:3, pages 273-283.
Crossref
Crossref
Keith Bodger. (2011) Cost Effectiveness of Treatments for Inflammatory Bowel Disease. PharmacoEconomics 29:5, pages 387-401.
Crossref
Crossref
Nanda Venu & Russell D. Cohen. 2011. Inflammatory Bowel Disease. Inflammatory Bowel Disease
295
313
.
Sudha A. Anupindi, Rama Ayyala, Judith Kelsen, Petar Mamula & Kimberly E. Applegate. 2011. Evidence-Based Imaging. Evidence-Based Imaging
571
591
.
Paloma Hernández-Sampelayo, Montserrat Seoane, Lorena Oltra, Laura Marín, Antonio Torrejón, María Isabel Vera, Valle García, Pablo Lázaro, Elizabeth Parody, Antonio J. Blasco & Francisco Casellas. (2010) Contribution of nurses to the quality of care in management of inflammatory bowel disease: A synthesis of the evidence. Journal of Crohn's and Colitis 4:6, pages 611-622.
Crossref
Crossref
R. D. COHEN, A. P. YU, E. Q. WU, J. XIE, P. M. MULANI & J. CHAO. (2010) Systematic review: the costs of ulcerative colitis in Western countries. Alimentary Pharmacology & Therapeutics 31:7, pages 693-707.
Crossref
Crossref
Russell D. Cohen. (2010) The pharmacoeconomics of biologic therapy for IBD. Nature Reviews Gastroenterology & Hepatology 7:2, pages 103-109.
Crossref
Crossref
Sudha Anupindi, Rama Ayyala, Judith Kelsen, Petar Mamula & Kimberly E. Applegate. 2010. Evidence-Based Imaging in Pediatrics. Evidence-Based Imaging in Pediatrics
487
507
.
Johan Mesterton, Linus Jönsson, Sven H.C. Almer, Ragnar Befrits, Ingalill Friis-Liby & Stefan Lindgren. (2009) Resource use and societal costs for Crohnʼs disease in Sweden. Inflammatory Bowel Diseases 15:12, pages 1882-1890.
Crossref
Crossref
Edward V. LoftusJrJr, Scott J. Johnson, Andrew P. Yu, Eric Q. Wu, Jingdong Chao & Parvez M. Mulani. (2009) Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs disease. European Journal of Gastroenterology & Hepatology 21:11, pages 1302-1309.
Crossref
Crossref
Rebecca R. Cannom, Andreas M. Kaiser, Glenn T. Ault, Robert W. BeartJR.JR. & David A. Etzioni. (2009) Inflammatory Bowel Disease in the United States from 1998 to 2005: Has Infliximab Affected Surgical Rates?. The American Surgeon 75:10, pages 976-980.
Crossref
Crossref
Sunanda V. Kane, Jingdong Chao & Parvez M. Mulani. (2009) Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Advances in Therapy 26:10, pages 936-946.
Crossref
Crossref
Andrew P. Yu, Scott Johnson, Si-Tien Wang, Pavel Atanasov, Jackson Tang, Eric Wu, Jingdong Chao & Parvez M. Mulani. (2009) Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohnʼs Disease. PharmacoEconomics 27:7, pages 609-621.
Crossref
Crossref
Jan Seibel, Almut F. Molzberger, Torsten Hertrampf, Ute Laudenbach-Leschowski & Patrick Diel. (2009) Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. European Journal of Nutrition 48:4, pages 213-220.
Crossref
Crossref
Sudha A. Anupindi & Kassa Darge. (2009) Imaging choices in inflammatory bowel disease. Pediatric Radiology 39:S2, pages 149-152.
Crossref
Crossref
R. Caprilli, E. Angelucci & V. Clemente. (2008) Recent advances in the management of Crohn's disease. Digestive and Liver Disease 40:9, pages 709-716.
Crossref
Crossref